Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
B cell modulation of immune dysfunction in pediatric minimal change disease
FY 2016-17
Summary
Nephrotic syndrome is the most common kidney disease in children causing frequently recurring episodes of protein loss in the urine and other debilitating symptoms. Over 90% of affected children have one type of nephrotic syndrome called minimal change disease (MCD). The treatment of MCD has been dominated by the use of steroids and other immune-suppressive drugs, all of which are associated with heavy toxicity. Targeted therapies do not exist since the cause of MCD is unknown. However, several lines of evidence establish MCD as a disease of the immune system involving one subset of immune cells called T cells. Research on T cells in MCD has been contradictory and inconclusive, and this is largely because study populations were non-generalizable and study designs lacked modern immunological expertise. Recently, rituximab (a B cell-targeting drug) was used to efficiently treat children with MCD, thereby implicating B cells in the disease process. As it is already well established that T and B cells help one another in orchestrating immune responses, the T-B cell crosstalk serves as a novel vantage point in determining the cause of MCD. We hypothesize that the efficacy of rituximab in MCD is a consequence of the targeted killing of disease-promoting B cell subsets that push T cell responses towards kidney injury. We propose to study MCD in the perspective of both T cells and B cells by deeply characterizing the immune systems of affected children before and after rituximab treatment, and in the presence or absence of active MCD. In doing so, we will determine a disease-promoting immune profile consistent with the disease setting. Our findings will help develop prognostic tests and targeted therapies for MCD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367036
Name
Al-Aubodah Tho-Alfakar
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
B cell modulation of immune dysfunction in pediatric minimal change disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmunity; B Cells; Clinical Immunology; Cytokines; Immune Regulation; Minimal Change Disease; Nephrotic Syndrome; Pediatrics; Rituximab; T Cells
Abstract
Nephrotic syndrome is the most common kidney disease in children causing frequently recurring episodes of protein loss in the urine and other debilitating symptoms. Over 90% of affected children have one type of nephrotic syndrome called minimal change disease (MCD). The treatment of MCD has been dominated by the use of steroids and other immune-suppressive drugs, all of which are associated with heavy toxicity. Targeted therapies do not exist since the cause of MCD is unknown. However, several lines of evidence establish MCD as a disease of the immune system involving one subset of immune cells called T cells. Research on T cells in MCD has been contradictory and inconclusive, and this is largely because study populations were non-generalizable and study designs lacked modern immunological expertise. Recently, rituximab (a B cell-targeting drug) was used to efficiently treat children with MCD, thereby implicating B cells in the disease process. As it is already well established that T and B cells help one another in orchestrating immune responses, the T-B cell crosstalk serves as a novel vantage point in determining the cause of MCD. We hypothesize that the efficacy of rituximab in MCD is a consequence of the targeted killing of disease-promoting B cell subsets that push T cell responses towards kidney injury. We propose to study MCD in the perspective of both T cells and B cells by deeply characterizing the immune systems of affected children before and after rituximab treatment, and in the presence or absence of active MCD. In doing so, we will determine a disease-promoting immune profile consistent with the disease setting. Our findings will help develop prognostic tests and targeted therapies for MCD.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Al-Aubodah, Tho-Alfakar
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~